Phase II Study of Pegylated Liposomal Doxorubicin (Doxil), Low Frequency Dexamethasone and Revlimid (Dd-R) [lenalidomide] in Newly Diagnosed Multiple Myeloma.

Trial Profile

Phase II Study of Pegylated Liposomal Doxorubicin (Doxil), Low Frequency Dexamethasone and Revlimid (Dd-R) [lenalidomide] in Newly Diagnosed Multiple Myeloma.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2014

At a glance

  • Drugs Dexamethasone (Primary) ; Doxorubicin liposomal (Primary) ; Lenalidomide (Primary)
  • Indications Multiple myeloma
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Apr 2013 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 14 Feb 2013 Planned end date changed from 1 Nov 2012 to 1 Sep 2013 as reported by ClincialTrials.gov.
    • 12 Apr 2012 Planned End Date changed from 1 Jun 2012 to 1 Nov 2012 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top